FFA
XERS icon

Farther Finance Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Farther Finance Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$28.4K Buy
2,973
+316
+12% +$2.67K ﹤0.01% 3874
2026
Q2 		$20.7K Buy
2,657
+188
+8% +$1.2K ﹤0.01% 3939
2026
Q1 		$14.9K Sell
2,469
-102
-4% -$676 ﹤0.01% 3851
2025
Q4 		$20.2K Buy
2,571
+190
+8% +$1.5K ﹤0.01% 3433
2025
Q3 		$19.4K Buy
2,381
+2,200
+1,215% +$14.6K ﹤0.01% 3061
2025
Q2 		$845 Hold
181
– – ﹤0.01% 3938
2025
Q1 		$919 Hold
181
– – ﹤0.01% 3636
2024
Q4 		$614 Hold
181
– – ﹤0.01% 3400
2024
Q3 		$516 Buy
181
+7
+4% +$18 ﹤0.01% 3418
2024
Q2 		$378 Buy
174
+71
+69% +$143 ﹤0.01% 3339
2024
Q1 		$220 Hold
103
– – ﹤0.01% 3248
2023
Q4 		$242 Buy
+103
New +$190 ﹤0.01% 3186

Other funds holding XERS

VFP
Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's XERS Position: Q3 2026 in Review

Farther Finance Advisors increased its Xeris Biopharma Holdings (XERS) stake by 12% in Q3 2026, buying an estimated $2.67K and bringing the position to 2,973 shares worth $28.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3874.

Farther Finance Advisors first reported a position in XERS in Q4 2023 and has held it in 12 quarters since. 7 funds tracked by Wall St. Rank hold XERS as of Q3 2026.

  • Farther Finance Advisors held 2,973 shares of Xeris Biopharma Holdings worth $28.4K as of Q3 2026.
  • Farther Finance Advisors bought 316 Xeris Biopharma Holdings shares in Q3 2026, an estimated $2.67K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #3874 holding.
  • Farther Finance Advisors first reported a position in Xeris Biopharma Holdings in Q4 2023 and has held it in 12 quarters since.
  • 7 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.